Home › Funds › Willis Investment Counsel › ABT

Willis Investment Counsel position in ABT

ABBOTT LABORATORIES · Health Care

Willis Investment Counsel reported holding 345,349 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$34.1M, representing 1.73% of its reported portfolio and ranking #17 among its reported holdings. Willis Investment Counsel has disclosed ABT holdings in 6 of the last 6 reported quarters, going back to Q2 2025.

Latest position (Q3 2026)345.35K sh
Reported value held$34.13M
Portfolio Weight1.73%
First reportedQ2 2025
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Willis Investment Counsel's ABT position evolved

Willis Investment Counsel first disclosed a stake in ABT in Q2 2025 at 106,966 shares (US$14.5M). The position peaked in Q3 2026 at 345,349 shares, worth US$34.1M. Across 6 filings, Willis Investment Counsel increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 345,349 shares valued at US$34.1M. Notable position changes include a 86% increase in Q4 2025 (shares fell 18% over the following quarter), a 73% increase in Q2 2026 (shares rose 10% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2025 106.97K $14.55M New
Q3 2025 106.97K $14.33M Hold
Q4 2025 199.35K $24.98M Add
Q1 2026 199.35K $20.47M Hold
Q2 2026 345.35K $31.34M Add
Q3 2026 345.35K $34.13M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has Willis Investment Counsel held ABT?

Willis Investment Counsel has disclosed ABT holdings in 6 of the last 6 reported quarters, going back to Q2 2025.

What is Willis Investment Counsel's current position in ABT?

As of Q3 2026, Willis Investment Counsel holds 345.35K shares of ABT (ABBOTT LABORATORIES), valued at $34.13M, representing 1.73% of its reported portfolio and ranking #17.

Has Willis Investment Counsel been buying or selling ABT?

In the latest 13F filing (Q3 2026), Willis Investment Counsel held unchanged its position in ABT. The position peaked in Q3 2026 at 345.35K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.